Optimizing Outcomes in Hereditary Angioedema: Managed Care Approaches to Diagnosis, Treatment, and Patient Quality of Life

Program Description

Hereditary angioedema (HAE) is characterized by recurrent swelling of the skin and submucosal tissues, most commonly affecting the extremities, face, gastrointestinal tract, and airway. The management of HAE is complex, as frequency and severity of attacks vary widely between individuals and even within the same person over time. Acute on-demand treatment and prophylactic therapy options have emerged as the mainstays of HAE management. While each is effective, there are practical, safety, and economic limitations that affect real‑world use and patient quality of life. Challenges include burdensome routes of administration, treatment delays, breakthrough attacks despite prophylaxis, adverse effects, and high direct and system costs. This program will review clinical data for expanded long-term prophylaxis options in the HAE treatment landscape and focus on distinct profiles regarding efficacy, safety, and administration methods to support individualized treatment strategies. These expanded treatment options have the potential to reallocate healthcare expenditure from acute interventions toward preventive care strategies while simultaneously improving disease management. This discussion will also incorporate real-world data for long-term prophylaxis agents in HAE to equip managed care professionals and pharmacists to improve clinical, quality-of-life, and economic outcomes while still supporting patient access to appropriate agents for HAE treatment and management.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate the multifaceted clinical and economic impact of hereditary angioedema (HAE), encompassing treatment expenditures, healthcare utilization patterns, and the downstream effects of current management approaches on patient outcomes.
• Distinguish among current and emerging prophylactic therapies by assessing their comparative efficacy, safety profiles, and routes of administration to inform personalized and cost-conscious treatment decisions.
• Interpret recent innovations in on-demand HAE therapies and examine how these agents contribute to reducing attack burden, improving quality of life, and decreasing healthcare resource use.
• Identify managed care strategies to ensure timely access to HAE treatments, fostering continuity of care, and advancing evidence-based, value-oriented management strategies.

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-106-H01-P. The activity is available for CE credit through April 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Amanda Williams, PharmD, RPh, has the following relevant financial relationships with ineligible companies to disclose:

Employee of PBM: Gainwell Technologies

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Mark A. Malesker, PharmD, FCCP, FCCP, FCCM, ATSF, FASHP, BCPS

Pharmacy Times Continuing Education Planning Staff: Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Katie Naspo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms